single-dose pen.” The federal government has authorised a transition period for compounded versions of Eli Lilly’s Zepbound and Mounjaro. Compounded semaglutide, sold under Novo Nordisk’s ...

Mads Claus Rasmussen / Ritzau Scanpix / AFP / Getty Images Novo Nordisk's U.S.-listed shares fell Monday after it released the latest results for its developmental weight loss drug CagriSema.

Shares of Novo Nordisk slipped in Monday morning trading after the company announced results of its latest weight-loss drug trial. Novo's results from its Redefine 2 late-stage trial of ...

It has been estimated that 90% of medical device waste consists of single-use products or components, so a new initiative by Novo Nordisk to recycle pre-filled injection pens used by people living ...

Novo Nordisk announced that its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes lose 15.7% of their weight in a recent trial. That figure ...

Novo Nordisk is rolling out a new national marketing campaign for its GLP-1 juggernaut, teaming up with celebrities and other patients to show what life looks like in their “Ozempic Eras.” ...

Novo Nordisk shares fell after the pharmaceutical giant released fresh trial results for its CagriSema developmental weight-loss drug. The Danish company said CagriSema helped obese or overweight ...

Shares of Novo Nordisk (NYSE: NVO) are tumbling on Monday. The company's stock lost 8.9% as of 10:10 a.m. ET and was down as much as 9.2% earlier in the day. The drop comes as the S&P 500 ...

Novo Nordisk (NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its next-generation GLP-1 drug, CagriSema. The drug, a mix of cagrilintide and ...